Initial safety data from the MP0712 Phase 1/2a study is expected in the coming months, with comprehensive efficacy data in 2027. Traders should watch for interim data readouts as potential catalysts, but near-term stock movement is likely limited given the early stage. The partnership with Orano Med provides 212Pb supply security but no financial terms were disclosed.
Price Chart
Executive Summary
Molecular Partners announced first patient dosing in the US Phase 1/2a study of MP0712, a DLL3-targeting 212Pb-labeled Radio-DARPin for small cell lung cancer. Initial safety data expected in the coming months, with comprehensive efficacy data in 2027. This is an early clinical milestone with no financial or regulatory catalyst yet — the stock impact is likely modest.
Key Facts
- First patients dosed in US multicenter Phase 1/2a study of MP0712 (DLL3-targeting 212Pb-labeled Radio-DARPin)
- Five US sites recruiting; additional sites planned this year
- Initial data expected in the coming months; comprehensive efficacy data in 2027
- DLL3 expressed in >85% of small cell lung cancer tumors; low expression in healthy tissues
- Study uses matched-pair approach with 203Pb-labeled diagnostic imaging agent
- Partnership with Orano Med for 212Pb supply
Financial Impact
No financial data provided in the press release. Early clinical milestone with no revenue or cost figures disclosed.
Risk Factors
- Early-stage clinical data may not support safety or efficacy
- DLL3-targeting radiopharmaceuticals face competition from other modalities (e.g., bispecifics, ADCs)
- No financial terms of the Orano Med partnership disclosed; partnership risk if program fails
- Small market cap ($156M) amplifies binary risk on clinical data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3321081 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 9w ago | 6-K | $4.38 $3.99 | ▼ −8.90% | ▼ −10.15% | $3.81 (−13.01%) |
Jul 20, 2026 14w ago | 6-K | $4.00 $4.25 | ▲ +6.25% | ▲ +2.13% | $3.81 (−4.75%) |
Jul 16, 2026 14w ago | Press Release | $4.10 $4.21 | ▲ +2.68% | ▼ −0.93% | $3.81 (−7.07%) |
Jul 6, 2026 16w ago | Press Release | $4.00 $3.93 | ▼ −1.75% | ▼ −1.18% | $3.81 (−4.75%) |
Jul 2, 2026 16w ago | 6-K | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jul 2, 2026 16w ago | Press Release | $3.98 $3.93 | ▼ −1.26% | ▼ −0.84% | $3.81 (−4.27%) |
Jun 1, 2026 21w ago | 6-K | $3.95 $3.87 | ▼ −2.03% | ▼ −0.73% | $3.81 (−3.54%) |
May 12, 2026 24w ago | 6-K | $4.00 $3.71 | ▼ −7.25% | ▼ −6.64% | $3.81 (−4.75%) |
May 1, 2026 25w ago | Press Release | $4.24 $3.95 | ▼ −6.84% | ▼ −12.12% | $3.81 (−10.14%) |
Mar 30, 2026 30w ago | 6-K | $3.93 $4.28 | ▲ +8.91% | ▼ −3.69% | $3.81 (−3.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers